Vertex granted OK to market HCV drug Incivek in Canada
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals' hepatitis C virus (HCV) drug Incivek (telaprevir) has gained another approval, this time in Canada, where the disease affects about 250,000 people.